Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Methodologic lessons learned from hot flash studies
Autore:
Sloan, JA; Loprinzi, CL; Novotny, PJ; Barton, DL; Lavasseur, BI; Windschitl, H;
Indirizzi:
Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA Mayo Clin Rochester MN USA 55905 , Div Med Oncol, Rochester, MN 55905 USA CentraCare Clin, St Cloud, MN USA CentraCare Clin St Cloud MN USACentraCare Clin, St Cloud, MN USA Ann Arbor Reg Community Clin Oncol Program, Ann Arbor, MI USA Ann Arbor Reg Community Clin Oncol Program Ann Arbor MI USA rbor, MI USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 23, volume: 19, anno: 2001,
pagine: 4280 - 4290
SICI:
0732-183X(200112)19:23<4280:MLLFHF>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER SURVIVORS; TRANSDERMAL CLONIDINE; SYMPTOM DISTRESS; PAIN PATIENTS; DIARY; SEVERITY; HYDROCHLORIDE; FEASIBILITY; INVENTORY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Loprinzi, CL Mayo Clin, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin 200 1st St SW Rochester MN USA 55905 , MN 55905 USA
Citazione:
J.A. Sloan et al., "Methodologic lessons learned from hot flash studies", J CL ONCOL, 19(23), 2001, pp. 4280-4290

Abstract

Purpose : In the course of conducting a series of prospective clinical trials devoted to defining new treatment opportunities for hot flashes in cancer survivors, considerable experience has been acquired with related methodologic issues. This article has been written in response to many queries regarding this methodology. Patients and Methods: A series of seven different clinical trials that involved 968 patients was used for this work. Reliable and valid definitions of hot flash intensity were developed from patient-reported descriptions. Concomitant validity and reliability assessment of patient-completed diaries was undertaken to compare hot flash data with toxicity and quality-of-life (QOL) end points and to examine consistency across patient groups using variability analysis and correlation procedures. Parametric data from this meta-analysis was used to examine relative power considerations for the designof phase II and phase III clinical trials. Results: Daily diaries used in these studies exhibited consistency and reliability and had few missing data. Hot flash frequency and hot flash score (frequency multiplied by average severity) variables produced almost identical end point results. For phase III placebo-controlled studies, 50 patients per treatment arm seem appropriate to provide sufficient power specifications to detect a clinically meaningful change in hot flash activity. For phase II trials, 25 patients per trial seem to provide reasonable estimates of eventual hot flash efficacy to screen potential agents for more definitive testing. Conclusion: Given the data gained from these experiences, we can plan and carry out more efficient trials to identify efficacious agents for the reduction of hot flash activity. J Clin Oncol 19:4280-4290. (C) 2001 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 16:38:10